Helixconstraints and amino acid substitution in GLP-1 increase cAMP and insulin secretion but not beta-arrestin 2 signaling.

Saved in:
Bibliographic Details
Title: Helixconstraints and amino acid substitution in GLP-1 increase cAMP and insulin secretion but not beta-arrestin 2 signaling.
Authors: Plisson F; Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD 4072, Australia., Hill TA; Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD 4072, Australia. Electronic address: t.hill@imb.uq.edu.au., Mitchell JM; Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD 4072, Australia., Hoang HN; Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD 4072, Australia., de Araujo AD; Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD 4072, Australia., Xu W; Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD 4072, Australia., Cotterell A; Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD 4072, Australia., Edmonds DJ; Worldwide Medicinal Chemistry, Cardiovascular, Metabolic & Endocrine Diseases Research Unit, Pfizer Inc., Cambridge, MA 02140, United States., Stanton RV; Worldwide Medicinal Chemistry, Cardiovascular, Metabolic & Endocrine Diseases Research Unit, Pfizer Inc., Cambridge, MA 02140, United States., Derksen DR; Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., Groton, CT 06340, United States., Loria PM; Pharmacokinetics, Dynamics and Metabolism, Pfizer Inc., Groton, CT 06340, United States., Griffith DA; Worldwide Medicinal Chemistry, Cardiovascular, Metabolic & Endocrine Diseases Research Unit, Pfizer Inc., Cambridge, MA 02140, United States., Price DA; Worldwide Medicinal Chemistry, Cardiovascular, Metabolic & Endocrine Diseases Research Unit, Pfizer Inc., Cambridge, MA 02140, United States., Liras S; Worldwide Medicinal Chemistry, Cardiovascular, Metabolic & Endocrine Diseases Research Unit, Pfizer Inc., Cambridge, MA 02140, United States., Fairlie DP; Division of Chemistry and Structural Biology, Institute for Molecular Bioscience, The University of Queensland, St. Lucia, QLD 4072, Australia. Electronic address: d.fairlie@imb.uq.edu.au.
Source: European journal of medicinal chemistry [Eur J Med Chem] 2017 Feb 15; Vol. 127, pp. 703-714. Date of Electronic Publication: 2016 Oct 21.
Publication Type: Journal Article
Journal Info: Publisher: Editions Scientifiques Elsevier Country of Publication: France NLM ID: 0420510 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1768-3254 (Electronic) Linking ISSN: 02235234 NLM ISO Abbreviation: Eur J Med Chem Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1768-3254
DOI:10.1016/j.ejmech.2016.10.044